Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.
about
How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsAntiviral drug resistance: mechanisms and clinical implicationsAntiviral drug resistance of human cytomegalovirus.Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment.Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping.Analysis of ganciclovir-resistant human herpesvirus 6B clinical isolates using quenching probe PCR methodology.Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavirNovel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations.Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibilityClinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase.Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness.Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.Rapid detection of human cytomegalovirus UL97 and UL54 mutations directly from patient samplesEffect of cell culture conditions on the anticytomegalovirus activity of maribavir.Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors.Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients.
P2860
Q28069489-E6CBD557-F024-4981-94E4-9356C91B5E81Q28282376-77199684-D24D-490E-8E14-E64D7B062C37Q30430427-E452856B-B793-45A0-B683-288FD8F9AB13Q33876672-0A095A0F-47A4-47BE-89C3-A95CF863F11CQ34483416-EC43EB6E-DB87-43C6-95BA-608F2303F521Q34687313-015DA3E1-3D17-4AF9-B2DF-EFC9D8ACD0D2Q34742654-80179007-E6C0-44E5-A240-D6792C562DA1Q35036076-80752023-389E-4576-A18E-6E07E50CC29CQ35385659-CFB9A8A3-48CE-4D49-9E8E-730D520B7C80Q35596269-FF45235C-F9CE-47A1-B3D2-1E85C77353B2Q35635817-B660E87E-0CDF-4DA9-8B93-4F63D72424ECQ36423920-D84D3927-BE27-4F7C-AA10-3471D1285E9FQ37085793-5C0F85AE-910B-4BD2-A218-93B7A37E69C7Q37264338-E15688D7-AF29-4127-9B25-40C7C85BDAC6Q37671946-2605949E-BB01-4BE7-AA2F-54C75A113E76Q37713957-05ECB605-243D-4CB3-B18E-721090BAF821Q38067694-C1C69733-BE02-4B71-909C-42D3D2047E2FQ38324789-DC7E1B40-F75E-41BC-AA60-D52FB42453CFQ38370342-5BE2F8F8-FB81-492D-92FE-D20038FC6F27Q38665326-8E9C5C2F-7A44-42BF-B970-B998B518E4ADQ38779846-2328F696-D244-4662-AD96-0D0E78A626DEQ38818062-6457EBAE-1989-47E8-A66A-D96432AA96ECQ39074863-96C91E23-2E7F-445C-96CB-D6AED49D91C1Q39155340-2AB2EEF4-92FC-46D4-83A4-12580D53F96DQ39650785-CA1DC708-0E04-4CF1-A7D0-75AE29AE1A59Q39834653-0FAA2B29-32F9-4DB9-A8FB-A2882F3D7FF3Q40325104-B2AEDB62-3BF0-4F91-899D-DFAA4A78CB2DQ40399325-A83F9372-D0A5-49F3-AB23-A2D727DC5972Q40414645-43488A46-399A-4117-8671-70AA086E7752Q40483485-4A62C204-038A-4F33-9B08-0DB15C4E5253Q41060769-40B8E172-0B02-4288-AFB0-3A8C0B0CDD32Q41430486-6CBDA0C4-9D50-4EAF-8772-2662E027E415Q41473772-CDF97E93-D957-483F-995F-C2C93E6B8234Q41858999-6BCD78F9-F121-45E3-AA17-BAF3288F0C6DQ41893150-F3EB15BB-C36D-4429-9980-808433EDAB98Q42177603-7646E093-7245-4C3C-B30C-2D14BF0CB68BQ42280383-3B4AE2E4-3AE9-4DB1-8074-F1257E77208DQ42616123-AC2F2875-D738-4FA5-97CE-ADA433794DDFQ43248439-8BC1E966-CBFC-446C-AF2D-7E7EB9466D5BQ43869508-8FFBB31E-EC7D-4437-8989-9B70BB2E61C7
P2860
Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Phenotyping of cytomegalovirus ...... incorporating a reporter gene.
@en
type
label
Phenotyping of cytomegalovirus ...... incorporating a reporter gene.
@en
prefLabel
Phenotyping of cytomegalovirus ...... incorporating a reporter gene.
@en
P2093
P2860
P1476
Phenotyping of cytomegalovirus ...... incorporating a reporter gene.
@en
P2093
Gail I Marousek
Heather M Lichy
Laura C Van Wechel
Sunwen Chou
P2860
P304
P356
10.1128/AAC.49.7.2710-2715.2005
P407
P577
2005-07-01T00:00:00Z